These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 9205053

  • 1. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.
    Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR.
    Cancer Res; 1997 Jul 01; 57(13):2559-63. PubMed ID: 9205053
    [Abstract] [Full Text] [Related]

  • 2. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
    Matsubara S, Wada Y, Gardner TA, Egawa M, Park MS, Hsieh CL, Zhau HE, Kao C, Kamidono S, Gillenwater JY, Chung LW.
    Cancer Res; 2001 Aug 15; 61(16):6012-9. PubMed ID: 11507044
    [Abstract] [Full Text] [Related]

  • 3. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
    Latham JP, Searle PF, Mautner V, James ND.
    Cancer Res; 2000 Jan 15; 60(2):334-41. PubMed ID: 10667585
    [Abstract] [Full Text] [Related]

  • 4. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.
    Yu DC, Sakamoto GT, Henderson DR.
    Cancer Res; 1999 Apr 01; 59(7):1498-504. PubMed ID: 10197620
    [Abstract] [Full Text] [Related]

  • 5. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.
    Li Y, McCadden J, Ferrer F, Kruszewski M, Carducci M, Simons J, Rodriguez R.
    Cancer Res; 2002 May 01; 62(9):2576-82. PubMed ID: 11980652
    [Abstract] [Full Text] [Related]

  • 6. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T, Lin FF, Rao P, Lin MF.
    Prostate; 2003 Jun 01; 55(4):247-58. PubMed ID: 12712404
    [Abstract] [Full Text] [Related]

  • 7. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, Henderson DR.
    Cancer Res; 2001 Sep 01; 61(17):6428-36. PubMed ID: 11522637
    [Abstract] [Full Text] [Related]

  • 8. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts.
    Yu DC, Chen Y, Seng M, Dilley J, Henderson DR.
    Cancer Res; 1999 Sep 01; 59(17):4200-3. PubMed ID: 10485454
    [Abstract] [Full Text] [Related]

  • 9. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer.
    Lee SJ, Zhang Y, Lee SD, Jung C, Li X, Kim HS, Bae KH, Jeng MH, Kao C, Gardner T.
    Mol Ther; 2004 Dec 01; 10(6):1051-8. PubMed ID: 15564137
    [Abstract] [Full Text] [Related]

  • 10. Prostate-specific targeting using PSA promoter-based lentiviral vectors.
    Yu D, Chen D, Chiu C, Razmazma B, Chow YH, Pang S.
    Cancer Gene Ther; 2001 Sep 01; 8(9):628-35. PubMed ID: 11593331
    [Abstract] [Full Text] [Related]

  • 11. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
    Gotoh A, Ko SC, Shirakawa T, Cheon J, Kao C, Miyamoto T, Gardner TA, Ho LJ, Cleutjens CB, Trapman J, Graham FL, Chung LW.
    J Urol; 1998 Jul 01; 160(1):220-9. PubMed ID: 9628654
    [Abstract] [Full Text] [Related]

  • 12. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines.
    Lee SE, Jin RJ, Lee SG, Yoon SJ, Park MS, Heo DS, Choi H.
    Anticancer Res; 2000 Jul 01; 20(1A):417-22. PubMed ID: 10769689
    [Abstract] [Full Text] [Related]

  • 13. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
    Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver B, Heufelder AE, Tindall DJ, Young CY, Morris JC.
    Cancer Res; 1999 May 01; 59(9):2136-41. PubMed ID: 10232600
    [Abstract] [Full Text] [Related]

  • 14. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations.
    Suzuki S, Tadakuma T, Asano T, Hayakawa M.
    Cancer Res; 2001 Feb 15; 61(4):1276-9. PubMed ID: 11245419
    [Abstract] [Full Text] [Related]

  • 15. Intravenous injection of an immunoconjugate (anti-PSA-IgG conjugated to 5-fluoro-2'-deoxyuridine) selectively inhibits cell proliferation and induces cell death in human prostate cancer cell tumors grown in nude mice.
    Sinha AA, Quast BJ, Reddy PK, Elson MK, Wilson MJ.
    Anticancer Res; 1999 Feb 15; 19(2A):893-902. PubMed ID: 10368631
    [Abstract] [Full Text] [Related]

  • 16. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
    Lowe SL, Rubinchik S, Honda T, McDonnell TJ, Dong JY, Norris JS.
    Gene Ther; 2001 Sep 15; 8(18):1363-71. PubMed ID: 11571575
    [Abstract] [Full Text] [Related]

  • 17. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
    Akbulut H, Zhang L, Tang Y, Deisseroth A.
    Cancer Gene Ther; 2003 May 15; 10(5):388-95. PubMed ID: 12719708
    [Abstract] [Full Text] [Related]

  • 18. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors.
    Wu L, Matherly J, Smallwood A, Adams JY, Billick E, Belldegrun A, Carey M.
    Gene Ther; 2001 Sep 15; 8(18):1416-26. PubMed ID: 11571582
    [Abstract] [Full Text] [Related]

  • 19. Human prostate cancer progression models and therapeutic intervention.
    Chung LW, Kao C, Sikes RA, Zhau HE.
    Hinyokika Kiyo; 1997 Nov 15; 43(11):815-20. PubMed ID: 9436028
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.